Etanercept (Enbrel)
What studies of Etanercept (Enbrel) found
At a glance, by condition
Long COVID: C Might help, very uncertain
Based on the strongest evidence, studies with no comparison group (very low certainty): 3 findings, all C.
3 outcomes rated · see each below
How we got this
Each condition’s headline comes from its graded findings (one for each outcome and kind of study) rated with the highest certainty: the grade most of them share; a tie goes to the finding with the most people, then the most studies, then the outcome’s name. It sums up the grades below, and conditions are never combined.
What this means: Etanercept (Enbrel) might help some people with long COVID, but research can’t show it yet. If you’re thinking about it, talk it through with a doctor who knows ME/CFS or long COVID.
Ask about this treatment
The grades, in plain words
Each outcome gets a direction, a certainty and a letter read from the two. Certainty is judged with GRADE, the method Cochrane and WHO use.
- AHelpsImprovement, high certaintyProbably helpsImprovement, moderate certainty
- BMay helpImprovement, low certainty
- Etanercept (Enbrel) · Long COVID is hereCMight help, very uncertainImprovement, very low certaintyMixed resultsStudies disagree
- DLittle or no differenceStudies found little or no difference
- FHarmsIt made things worse
By symptom and daily life
Long COVID
Cognition (brain fog)1 study · 1 (few people) person received Etanercept (Enbrel) Improvement C
Why this grade: Improvement, very low certainty, from studies without a control group: no control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design); few people (1 in all).
Studies with no comparison group1 in the study · single dose · 25 mg, a single 25 mg perispinal etanercept dose (few people)
Cognition (brain fog) improved.
The evidence is very uncertain about the effect of etanercept (Enbrel) on cognition (brain fog) in long COVID. Improvement · very low certainty C
- No control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design)
- Few people (1 in all)
See the 1 study
-
Rapid improvement in severe long COVID following perispinal etanercept. (2022)
- People in the study
- 1 in the study
- Dose
- 25 mg, a single 25 mg perispinal etanercept dose
- Outcome
- Cognition
- Effect
- better
- Risk of bias
- case report or series (JBI checklist for case reports / case series); not rated with RoB 2 or ROBINS-I
Depression1 study · 1 (few people) person received Etanercept (Enbrel) Improvement C
Why this grade: Improvement, very low certainty, from studies without a control group: no control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design); few people (1 in all); not all results were tested against chance.
Studies with no comparison group1 in the study · single dose · 25 mg, a single 25 mg perispinal etanercept dose (few people)
Depression improved.
The evidence is very uncertain about the effect of etanercept (Enbrel) on depression in long COVID. Improvement · very low certainty C
- No control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design)
- Few people (1 in all)
- Not all results were tested against chance
See the 1 study
-
Rapid improvement in severe long COVID following perispinal etanercept. (2022)
- People in the study
- 1 in the study
- Dose
- 25 mg, a single 25 mg perispinal etanercept dose
- Outcome
- depression
- Effect
- better (not tested)
- Risk of bias
- case report or series (JBI checklist for case reports / case series); not rated with RoB 2 or ROBINS-I
Fatigue1 study · 1 (few people) person received Etanercept (Enbrel) Improvement C
Why this grade: Improvement, very low certainty, from studies without a control group: no control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design); few people (1 in all); not all results were tested against chance.
Studies with no comparison group1 in the study · single dose · 25 mg, a single 25 mg perispinal etanercept dose (few people)
Fatigue improved.
The evidence is very uncertain about the effect of etanercept (Enbrel) on fatigue in long COVID. Improvement · very low certainty C
- No control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design)
- Few people (1 in all)
- Not all results were tested against chance
See the 1 study
-
Rapid improvement in severe long COVID following perispinal etanercept. (2022)
- People in the study
- 1 in the study
- Dose
- 25 mg, a single 25 mg perispinal etanercept dose
- Outcome
- fatigue
- Effect
- better (not tested)
- Risk of bias
- case report or series (JBI checklist for case reports / case series); not rated with RoB 2 or ROBINS-I
Side effects
No study of this treatment alone reported side effects we could read.
Doses studied
What researchers used, as the papers print it; not a recommendation.
- 1Start
25 mg at the start
- 2Top dose
Most often 25 mg (1 of 1 studies)
Doses across 1 study
25 to 25 mg.
Each study’s dose, as printed
- 25 mg, a single 25 mg perispinal etanercept dose Rapid improvement in severe long COVID following perispinal etanercept. (2022)
All papers
- Rapid improvement in severe long COVID following perispinal etanercept.2022 · case report · 1 in the study
Summary
This case report describes one patient with severe long COVID brain dysfunction of 12 months duration; the setting was not reported. The patient received a single 25 mg perispinal etanercept dose. There was no comparison group; outcomes were assessed before versus after treatment. Standardized, validated measures were used to quantify cognition, depression, fatigue and neurological function, including the Montreal Cognitive Assessment, Beck Depression Index-II, Fatigue Assessment Scale, Controlled Oral Word Association Test, Trail Making Tests, Timed Finger-to-Nose Test, Self-Paced Walk Test, Sit-to-Stand Test and grip strength measured with a Jamar Dynamometer. Following perispinal etanercept administration, the authors report immediate neurological improvement. At 24 h, they report remarkable reductions in chronic post-COVID-19 fatigue and depression and significant measurable improvements in cognition, executive function, phonemic verbal fluency, balance, gait, upper limb coordination and grip strength. Cognition, depression and fatigue were examined at 29 days; each remained substantially improved. Side effects and withdrawals were not reported. The authors state that clinical trials of perispinal etanercept for long COVID are urgently necessary.
- Systematic review of interventions for mental health, cognition and psychological well-being in long COVID.2024 · systematic review
Summary
This systematic review aimed to identify and synthesise publicly available research testing treatments for mental health, cognition and psychological well-being in long COVID. It included 33 documents representing 31 studies and 2477 participants recruited across four continents. The studies covered 7 psychosocial, 5 pharmaceutical, 3 natural supplement, 9 neurocognitive, 2 physical rehabilitation and 5 integrated intervention studies; 11 were RCTs, 2 non-randomised controlled trials, 10 uncontrolled trials, 7 case studies or series and 1 qualitative study. Some controlled trials reported significant group×time interactions: vortioxetine for depression and health-related QoL but not cognition; hyperbaric oxygen for total cognition and psychological distress only; high-definition transcranial direct current stimulation for cognitive and psychosocial fatigue, anxiety and QoL; and a programme combining non-invasive cognitive stimulation and guided mindfulness for mental fatigue, anxiety, depression, mood disturbance and several cognitive domains. Other trials reported no significant group×time interaction, including an adaptogen formulation and the ReCOVERY app. Many uncontrolled studies reported significant prepost improvements, but the authors state these cannot be definitively associated with treatment without a control group. Counts of people who worsened or stopped and side-effect counts were not reported in the recorded data; the authors note many studies did not report adverse events.
- Research evidence on the management of the cognitive impairment component of the post-COVID condition: a qualitative systematic review.2024 · systematic review
Summary
This qualitative systematic review asked which treatments have been studied for cognitive impairment after COVID-19. The search covered PubMed, Scopus, and ProQuest up to December 31, 2023, and included 29 studies of post-COVID cognitive impairment; samples ranged from single patients to larger groups. Treatments included cognitive remediation, multidisciplinary rehabilitation, noninvasive brain stimulation, hyperbaric oxygen, pharmacological and nutraceutical agents, neurofeedback, photobiomodulation, and meditation. Comparisons, where reported, included control, sham, placebo, or usual-care groups. Cognitive functioning was assessed with standardized tests, test batteries, or structured interviews. Findings varied. A randomized sham-controlled HBOT trial in 37 subjects reported significant improvements in global cognitive functioning, attention, and executive functions versus control. A famotidine RCT reported significantly improved global cognition in the treatment group (N = 25). A donepezil RCT found no differences between N = 15 and N = 10 in memory after 4 and 12 weeks. A tDCS randomized sham-controlled trial in 23 subjects found no significant effects on executive functioning and processing speed after eight tDCS sessions. A remote multidisciplinary RCT found no significant differences between N = 52 and N = 48. A multidisciplinary study in 80 subjects found no significant improvements in memory and attention at discharge. Other studies reported improvements in smaller or uncontrolled samples. No worsening, stopping, or side effects were reported in the recorded data. The authors state limitations including heterogeneity, lack of long-term follow-up, and under-characterization of samples.